Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitotane therapeutic drug monitoring in adrenocortical cancer
ACTRN12613000058774Phase 4Recruiting
- Sponsor
- Calvary Mater Newcastle
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitotane in adrenal cancer (ACC), sponsored by Calvary Mater Newcastle. Primary endpoint: Relationship between plasma mitotane/metabolite levels and toxicity and response. Started Jan 2013; status: recruiting.
02
Drugs
mitotane
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on ACTRN12613000058774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000058774.